Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Engineering Biosensors to Enhance Monoterpene Indole Alkaloid Production in Yeast.

bioRxiv : the preprint server for biology·2026
Same author

Ligify 2.0: a web server for predicted small molecule biosensors.

Nucleic acids research·2026
Same author

groovDB in 2026: a community-editable database of small molecule biosensors.

Nucleic acids research·2025
Same author

Rational design of selective bispecific EPO-R/CD131 agonists.

bioRxiv : the preprint server for biology·2025
Same author

A coronaviral pore-replicase complex links RNA synthesis and export from double-membrane vesicles.

Science advances·2024
Same author

Ten Years of the Synthetic Biology Summer Course at Cold Spring Harbor Laboratory.

ACS synthetic biology·2024

相关实验视频

Updated: Jun 7, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.1K

选择性双特异性EPO-R/CD131激动剂的合理设计

Kailyn E Doiron1,2,3, Jeffrey C Way1,2, Pamela A Silver1,2

  • 1Department of Systems Biology, Harvard Medical School, 210 Longwood Avenue, Boston, MA 02115, USA.

Protein engineering, design & selection : PEDS
|November 9, 2025
PubMed
概括

研究人员开发了新的双特异性蛋白质来激活EPO-R/CD131信号,为细胞因子受体激动剂开发和理解EPO-R/CD131生物学提供了一种新方法.

关键词:
细胞因子细胞因子红色素是人为的蛋白质.神经保护是一种神经保护.在STAT5中,我们使用了STAT5.scFvv 在线阅读

更多相关视频

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.8K
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.6K

相关实验视频

Last Updated: Jun 7, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.1K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.8K
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.6K

科学领域:

  • 生物化学和分子生物学
  • 免疫学 免疫学 免疫学
  • 结构生物学 结构生物学

背景情况:

  • 红素 (EPO) 信号传递对细胞生存至关重要,通过EPO-R/EPO-R或EPO-R/CD131复合体起作用.
  • 通过EPO-R/CD131发送EPO信号的精确机制和结构基础仍然不完全理解和辩论.

研究的目的:

  • 构建EPO-R/CD131综合体的结构模型.
  • 设计和验证选择性激活EPO-R/CD131信号的双特异性蛋白质.

主要方法:

  • 对EPO-R/CD131综合体的结构建模.
  • 对抗EPO-R和抗CD131双特异性蛋白质 (tandem scFv,双特异性抗体格式) 的设计和工程.
  • 评估STAT5酸化作为EPO-R/CD131激活的读数.

主要成果:

  • 开发了一个EPO-R/CD131的结构模型.
  • 工程双特异性蛋白质,特别是在tandem scFv和双特异性抗体格式,选择性激活EPO-R/CD131.
  • 通过独立于EPO-R/EPO-R参与的STAT5酸化来确认激活.
  • 修改绑定域的排列和链接器的长度与结构模型保持一致.

结论:

  • 双特异性支架是开发细胞因子受体激活剂的有效工具.
  • 这项研究为进一步研究EPO-R/CD131生物学提供了基础.
  • 这些发现支持了未来临床开发EPO-R/CD131向治疗药物的潜力.